¼¼°èÀÇ AHDS(Allan-Herndon-Dudley Syndrome) Ä¡·á ½ÃÀå : Ä¡·á À¯Çüº°, ÃÖÁ¾»ç¿ëÀÚº°, Áö¿ªº°
Global Allan-Herndon-Dudley Syndrome Treatment Market, By Treatment Type (Gene Therapy, Hormone Therapy), By End User (Hospital, Specialty Clinics, Others), By Geography (North America, Europe, Asia Pacific, Latin America, Middle East and Africa)
»óǰÄÚµå : 1708858
¸®¼­Ä¡»ç : Coherent Market Insights
¹ßÇàÀÏ : 2025³â 03¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹®
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 4,500 £Ü 6,197,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 7,000 £Ü 9,640,000
PDF (Multi User License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷Àå¿¡¼­ 7¸í±îÁö ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 10,000 £Ü 13,772,000
PDF (Enterprise User License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

¼¼°è AHDS(Allan-Herndon-Dudley Syndrome) Ä¡·áÁ¦ ½ÃÀåÀº 2025³â¿¡´Â 1,410¸¸ ´Þ·¯·Î ÃßÁ¤µÇ¸ç 2032³â¿¡´Â 2,080¸¸ ´Þ·¯¿¡ ´ÞÇϰí, 2025-2032³â 5.7%ÀÇ ¿¬Æò±Õ ¼ºÀå·ü(CAGR)À» º¸ÀÏ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

º¸°í ¹üÀ§ º¸°í¼­ »ó¼¼ ³»¿ë
±âÁØ ¿¬µµ 2024³â 2025³â ½ÃÀå ±Ô¸ð 1,410¸¸ ´Þ·¯
½ÇÀû µ¥ÀÌÅÍ 2020-2024³â ¿¹Ãø ±â°£ 2025-2032³â
¿¹Ãø ±â°£(2025-2032³â) CAGR 5.70% 2032³â °¡Ä¡ ¿¹Ãø 2,080¸¸ ´Þ·¯
±×¸². 2025³â Áö¿ªº° AHDS(Allan-Herndon-Dudley Syndrome) Ä¡·áÁ¦ ¼¼°è ½ÃÀå Á¡À¯À²(%)
Global Allan-Herndon-Dudley Syndrome Treatment Market-IMG1

AHDS(Allan-Herndon-Dudley Syndrome)(AHDS)Àº MCT8 À¯ÀüÀÚÀÇ µ¹¿¬º¯ÀÌ·Î ÀÎÇØ ¹ß»ýÇÏ´Â Èñ±ÍÇÑ À¯Àü ÁúȯÀÔ´Ï´Ù. ÀÌ·¯ÇÑ µ¹¿¬º¯ÀÌ´Â °©»ó¼± È£¸£¸óÀÌ Ç÷¾×³úÀ庮À» Åë°úÇÏ´Â °©»ó¼± È£¸£¸ó ¼ö¼Û Àå¾Ö¸¦ ÃÊ·¡Çϸç, ÇöÀç AHDS¿¡ ´ëÇÑ Ä¡·á ¿É¼ÇÀº Áõ»ó Á¶ÀýÀ» ¸ñÇ¥·Î ÇÏ´Â Á¦ÇÑÀûÀÎ Ä¡·á¹ýÀÔ´Ï´Ù. Ä¡·áÀÇ Ã¹ ¹øÂ° ¼±ÅÃÀº °©»ó¼± È£¸£¸ó º¸ÃæÁ¦ÀÎ Æ®¸®¿ä¿Àµå »çÀ̷δÑ(T3)À» ÅëÇÑ °©»ó¼± È£¸£¸ó º¸Ãæ¿ä¹ýÀ¸·Î, T3 º¸ÃæÁ¦´Â ³úÀÇ °©»ó¼± È£¸£¸ó ¼öÄ¡¸¦ ȸº¹½ÃÄÑ ½Å°æ ¹ß´Þ°ú ±â´ÉÀ» °³¼±ÇÏ´Â µ¥ µµ¿òÀÌ µË´Ï´Ù. ±×·¯³ª °í¿ë·®ÀÇ T3´Â ¶§¶§·Î ¶³¸², °ú´ÙÇൿ, ºÎÁ¤¸Æ°ú °°Àº ºÎÀÛ¿ëÀ» À¯¹ßÇÒ ¼ö ÀÖ½À´Ï´Ù. ¶Ç ´Ù¸¥ ´ë¾ÈÀº ¼¼Æ÷ ³»¿¡¼­ T4°¡ ¸»ÃÊ¿¡¼­ Ȱ¼ºÇü T3·Î ÀüȯµÇ´Â °Í¿¡ ÀÇÁ¸Çϴ Ƽ·Ï½Å(T4) ¿ä¹ýÀÔ´Ï´Ù. ÀÌ °£Á¢ÀûÀÎ Ä¡·á¹ýÀº MCT8 µ¹¿¬º¯À̰¡ È£¸£¸óÀÇ ¼ö¼Û°ú Ȱ¼ºÈ­¸¦ ¾ïÁ¦Çϱ⠶§¹®¿¡ ±×´ÙÁö È¿°úÀûÀÌÁö ¾Ê½À´Ï´Ù.

»õ·Î¿î À¯ÀüÀÚ Ä¡·á´Â AHDSÀÇ ±Ùº»ÀûÀÎ À¯ÀüÀû ¿øÀÎÀ» Á÷Á¢ÀûÀ¸·Î Ä¡·áÇÒ ¼ö ÀÖ´Â À¯¸ÁÇÑ ¿¬±¸ Á¢±Ù¹ýÀÔ´Ï´Ù. À¯ÀüÀÚ Ä¡·á´Â MCT8 À¯ÀüÀÚÀÇ Á¤»ó »çº»À» ȯÀÚÀÇ ¼¼Æ÷¿Í Á¶Á÷¿¡ µµÀÔÇÏ¿© µ¹¿¬º¯ÀÌµÈ À¯ÀüÀÚ¸¦ ´ëüÇÕ´Ï´Ù. ¾ÆÁ÷ ¿¬±¸ Ãʱ⠴ܰèÀÌÁö¸¸, À̴ ȣ¸£¸ó ¼ö¼Û °áÇÔÀ» ±³Á¤ÇÏ¿© Æò»ý µ¿¾È °©»ó¼± º¸ÃæÀÌ ÇÊ¿äÇÏÁö ¾Ê°Ô ÇÒ ¼ö ÀÖ½À´Ï´Ù. ´Ù¸¸, È¿°úÀûÀÌ°í ¾ÈÀüÇÑ À¯ÀüÀÚ µµÀÔ º¤ÅÍÀÇ °³¹ß°ú ƯÁ¤ MCT8 µ¹¿¬º¯ÀÌ¿¡ µû¶ó ȯÀÚ °³°³Àο¡ ¸Â´Â Ä¡·á¹ýÀ» °³¹ßÇØ¾ß ÇÏ´Â µîÀÇ °úÁ¦°¡ ³²¾ÆÀÖ½À´Ï´Ù. ÇâÈÄ AHDSÀÇ Çõ½ÅÀûÀÎ Ä¡·á¹ýÀ¸·Î À¯ÀüÀÚ Ä¡·á¸¦ °ËÁõÇϱâ À§ÇØ Ãß°¡ ¿¬±¸°¡ ÁøÇà ÁßÀÔ´Ï´Ù.

½ÃÀå ¿ªÇÐ:

¼¼°è AHDS(Allan-Herndon-Dudley Syndrome)(MCT8 °á¼ÕÁõ) Ä¡·áÁ¦ ½ÃÀåÀº ÁÖ·Î AHDSÀÇ À¯º´·ü Áõ°¡¿¡ ÈûÀÔ¾î ¿¹Ãø ±â°£ µ¿¾È ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ¿¹¸¦ µé¾î, 2020³â 1¿ù 16ÀÏ ¹Ì±¹ ±¹¸³»ý¹°°øÇÐÁ¤º¸¼¾ÅÍ(NCBI)°¡ ¹ßÇ¥ÇÑ ÀÚ·á¿¡ µû¸£¸é, ¾à 15³â µ¿¾È 160¸í ÀÌ»óÀÇ È¯ÀÚ°¡ È®ÀεǾî ÀÌ ÁõÈıºÀº Áö±Ý±îÁö »ý°¢Çß´ø °Íº¸´Ù ´õ ÈçÇÑ ÁúȯÀÓÀ» ½Ã»çÇϰí ÀÖ½À´Ï´Ù.

¿¬±¸ÀÇ ÁÖ¿ä Æ¯Â¡

¸ñÂ÷

Á¦1Àå Á¶»ç ¸ñÀû°ú ÀüÁ¦Á¶°Ç

Á¦2Àå ½ÃÀå Àü¸Á

Á¦3Àå ½ÃÀå ¿ªÇÐ, ±ÔÁ¦, µ¿Ç⠺м®

Á¦4Àå ¼¼°èÀÇ AHDS(Allan-Herndon-Dudley Syndrome) Ä¡·á ½ÃÀå - Äڷγª¹ÙÀÌ·¯½º(COVID-19) ÆÒµ¥¹ÍÀÇ ¿µÇâ

Á¦5Àå AHDS(Allan-Herndon-Dudley Syndrome) Ä¡·á ½ÃÀå, Ä¡·á À¯Çüº°, 2020³â-2032³â

Á¦6Àå AHDS(Allan-Herndon-Dudley Syndrome) Ä¡·á ½ÃÀå, ÃÖÁ¾»ç¿ëÀÚº°, 2020³â-2032³â

Á¦7Àå AHDS(Allan-Herndon-Dudley Syndrome) Ä¡·á ½ÃÀå, Áö¿ªº°, 2020³â-2032³â

Á¦8Àå °æÀï ±¸µµ

Á¦9Àå ¼½¼Ç

LSH
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Allan-Herndon-Dudley Syndrome Treatment Market is estimated to be valued at USD 14.1 Mn in 2025 and is expected to reach USD 20.8 Mn by 2032, growing at a compound annual growth rate (CAGR) of 5.7% from 2025 to 2032.

Report Coverage Report Details
Base Year: 2024 Market Size in 2025: USD 14.1 Mn
Historical Data for: 2020 To 2024 Forecast Period: 2025 To 2032
Forecast Period 2025 to 2032 CAGR: 5.70% 2032 Value Projection: USD 20.8 Mn
Figure. Global Allan-Herndon-Dudley Syndrome Treatment Market Share (%), By Region 2025
Global Allan-Herndon-Dudley Syndrome Treatment Market - IMG1

Allan-Herndon-Dudley syndrome (AHDS) is a rare genetic disorder caused by mutations in the MCT8 gene. These mutations result in impaired thyroid hormone transport across the blood-brain barrier. Current treatment options for AHDS are limited and aim to manage symptoms. The first line of treatment involves thyroid hormone replacement therapy with triiodothyronine (T3). T3 supplements help restore thyroid hormone levels in the brain to improve neurological development and function. However, high T3 doses sometimes cause side effects like tremors, hyperactivity, and irregular heartbeat. The other option is thyroxine (T4) therapy which relies on the peripheral conversion of T4 to active T3 within cells. This indirect method of treatment is not very effective as the MCT8 mutations disrupt hormone transportation and activation.

Emerging gene therapy is a promising investigational approach to directly treat the underlying genetic cause of AHDS. In gene therapy, a normal copy of the MCT8 gene would be delivered into the patient's cells and tissues to replace the mutated one. Though still in early research phase, this could correct the hormone transport defect and eliminate the need for lifelong thyroid supplementation. Challenges include developing effective and safe gene delivery vectors and treatments needing to be tailored to individual patients based on their specific MCT8 mutations. More research is underway to validate gene therapy as an innovative treatment for AHDS in the future.

Market Dynamics:

The global Allan-Herndon-Dudley syndrome (AHDS) (MCT8 deficiency) treatment market is mainly driven by the increasing prevalence of AHDS is expected to propel the market growth over the forecast period. For instance, according to the data published by the National Center for Biotechnology Information (NCBI) in January 16, 2020, the identification of more than 160 affected individuals in approximately 15 years suggests that the syndrome is more common than previously thought.

Key features of the study:

Detailed Segmentation:

Table of Contents

1. Research Objectives and Assumptions

2. Market Purview

3. Market Dynamics, Regulations, and Trends Analysis

4. Global Allan-Herndon-Dudley syndrome (AHDS) (MCT8 deficiency) Treatment Market - Impact of Coronavirus (COVID-19) Pandemic

5. Global Allan-Herndon-Dudley syndrome (AHDS) (MCT8 deficiency) Treatment Market, By Treatment Type, 2020-2032, (US$ Mn)

6. Global Allan-Herndon-Dudley syndrome (AHDS) (MCT8 deficiency) Treatment Market, By End User, 2020-2032, (US$ Mn)

7. Global Allan-Herndon-Dudley syndrome (AHDS) (MCT8 deficiency) Treatment Market, By Region, 2020-2032, (US$ Mn)

8. Competitive Landscape

9. Section

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â